The adjustment in price target by Oppenheimer, while maintaining an Outperform rating, suggests a continued positive outlook on UroGen Pharma with a slight moderation in expectations. This could lead to a neutral short-term impact on the stock as the market digests the minor adjustment in valuation expectations.